Antifibrinolytic mechanisms in acute airway injury after sulfur mustard analog inhalation

American Journal of Respiratory Cell and Molecular Biology

Volumn 51, Issue 4, 2014, Pages 559-567

  Rancourt, Raymond C ^a,b   Ahmad, Aftab ^a   Veress, Livia A ^a   Rioux, Jacqueline S ^a   Garlick, Rhonda B ^a   White, Carl W ^a  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Lung injury; Plasminogen activator inhibitor 1; Sulfur mustard; Thrombin activatable fibrinolysis inhibitor; 2 antiplasmin

Indexed keywords

2-CHLOROETHYL ETHYL SULFIDE; ALPHA 2 ANTIPLASMIN; ANTIFIBRINOLYTIC AGENT; CHEMICAL WARFARE AGENT; MUSTARD GAS; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ACUTE LUNG INJURY; AIRWAY OBSTRUCTION; ANALOGS AND DERIVATIVES; ANIMAL; CAPILLARY PERMEABILITY; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; EXPOSURE; FIBRINOLYSIS; LUNG; LUNG GAS EXCHANGE; LUNG LAVAGE; MALE; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; TIME; TOXICITY;

ACUTE LUNG INJURY; AIRWAY OBSTRUCTION; ALPHA-2-ANTIPLASMIN; ANIMALS; ANTIFIBRINOLYTIC AGENTS; BLOOD-AIR BARRIER; BRONCHOALVEOLAR LAVAGE FLUID; CAPILLARY PERMEABILITY; CARBOXYPEPTIDASE B2; CHEMICAL WARFARE AGENTS; FIBRINOLYSIS; INHALATION EXPOSURE; LUNG; MALE; MUSTARD GAS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 84907498962     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2014-0012OC     Document Type: Article

References (23)

1. Geraci MJ. Mustard gas: imminent danger or eminent threat? Ann Pharmacother 2008;42:237-246.
2. Eisenmenger W, Drasch G, von Clarmann M, Kretschmer E, Roider G. Clinical and morphological findings on mustard gas [bis(2-chloroethyl) sulfide] poisoning. J Forensic Sci 1991;36:1688-1698.
3. Willems Jl. Clinical management of mustard gas casualties. Ann Med Mil Belg 1989;3:1-61.
4. Lawley PD, Brookes P. Molecular mechanism of the cytotoxic action of difunctional alkylating agents and of resistance to this action. Nature 1965;206:480-483.
5. Hofstra JJ, Vlaar AP, Knape P, Mackie DP, Determann RM, Choi G, van der Poll T, Levi M, Schultz MJ. Pulmonary activation of coagulation and inhibition of fibrinolysis after burn injuries and inhalation trauma. J Trauma 2011;70:1389-1397.
6. Idell S, Koenig KB, Fair DS, Martin TR, McLarty J, Maunder RJ. Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol 1991;261:L240-L248.
7. Scotton CJ, Krupiczojc MA, Konigshoff M, Mercer PF, Lee YC, Kaminski N, Morser J, Post JM, Maher TM, Nicholson AG, et al. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest 2009;119:2550-2563.
8. Veress LA, O'Neill HC, Hendry-Hofer TB, Loader JE, Rancourt RC, White CW. Airway obstruction due to bronchial vascular injury after sulfur mustard analog inhalation. Am J Respir Crit Care Med 2010;182: 1352-1361.
9. Rancourt RC, Veress LA, Ahmad A, Hendry-Hofer TB, Rioux JS, Garlick RB, White CW. Tissue factor pathway inhibitor prevents airway obstruction, respiratory failure and death due to sulfur mustard analog inhalation. Toxicol Appl Pharmacol 2013;272:86-95.
10. Smith RE, Bissell ER, Mitchell AR, Pearson KW. Direct photometric or fluorometric assay of proteinases using substrates containing 7-amino-4-trifluoromethylcoumarin. Thromb Res 1980;17: 393-402.
11. Anderson DR, Yourick JJ, Moeller RB, Petrali JP, Young GD, Byers SL. Pathologic changes in rat lungs following acute sulfur mustard inhalation. Inhal Toxicol 1996;8:285-297.
12. Rancourt RC, Veress LA, Guo X, Jones TN, Hendry-Hofer TB, White CW. Airway tissue factor-dependent coagulation activity in response to sulfur mustard analog 2-chloroethyl ethyl sulfide. Am J Physiol Lung Cell Mol Physiol 2012;302:L82-L92.
13. Veress LA, Hendry-Hofer TB, Loader JE, Rioux JS, Garlick RB, White CW. Tissue plasminogen activator prevents mortality from sulfur mustard analog-induced airway obstruction. Am J Respir Cell Mol Biol 2013;48:439-447.
14. Takabayashi T, Kato A, Peters AT, Hulse KE, Suh LA, Carter R, Norton J, Grammer LC, Cho SH, Tan BK, et al. Excessive fibrin deposition in nasal polyps caused by fibrinolytic impairment through reduction of tissue plasminogen activator expression. Am J Respir Crit Care Med 2013;187:49-57.
15. Plow EF, Freaney DE, Plescia J, Miles LA. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 1986;103:2411-2420.
16. Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009;7:4-13.
17. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995;96: 2534-2538.
18. Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, Plow EF. Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. Biochemistry 1991;30:1682-1691.
19. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator: role of fibrin. J Biol Chem 1982;257:2912-2919.
20. Qin L, D'Alessandro-Gabazza CN, Aoki S, Gil-Bernabe P, Yano Y, Takagi T, Boveda-Ruiz D, Ramirez Marmol AY, San Martin Montenegro VT, Toda M, et al. Pulmonary hypertension is ameliorated in mice deficient in thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2010;8:808-816.
21. Naito M, Taguchi O, Kobayashi T, Takagi T, D'Alessandro-Gabazza CN, Matsushima Y, Boveda-Ruiz D, Gil-Bernabe P, Matsumoto T, Chelakkot-Govindalayathil AL, et al. Thrombin-activatable fibrinolysis inhibitor protects against acute lung injury by inhibiting the complement system. Am J Respir Cell Mol Biol 2013;49:646-653.
22. Renckens R, Roelofs JJ, ter Horst SA, van 't Veer C, Havik SR, Florquin S, Wagenaar GT, Meijers JC, van der Poll T. Absence of thrombinactivatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. J Immunol 2005;175:6764-6771.
23. Heath L, Ling S, Racz J, Mane G, Schmidt L, Myers JL, Tsai WC, Caruthers RL, Hirsch JC, Stringer KA. Prospective, longitudinal study of plastic bronchitis cast pathology and responsiveness to tissue plasminogen activator. Pediatr Cardiol 2011;32:1182-1189.